Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit Pourcet

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
The Journal of Clinical Investigation|February 20, 2018
Alternative macrophages in atherosclerosis: not always protective!Benoit Pourcet, Bart Staels
Frontiers in Immunology|August 28, 2020
Circadian Control of Inflammasome Pathways: Implications for Circadian MedicineBenoit Pourcet, Hélène Duez
Frontiers in Endocrinology|March 15, 2021
Nuclear Receptors in the Control of the NLRP3 Inflammasome PathwayHélène Duez, Benoit Pourcet
International Journal of Molecular Sciences|September 28, 2021
Nuclear Receptors and Clock Components in Cardiovascular DiseasesBenoit Pourcet, Hélène Duez
Medecine Sciences : M/S|September 12, 2022
[Nuclear receptors and circadian clock: Implications for inflammatory diseases]Hélène Duez, Benoit Pourcet
Cardiovascular Research|December 26, 2015
Perilipin2/adipophilin and ApoA-1 team up to combat atherosclerosisBenoit Pourcet, Bart Staels
Trends in Cardiovascular Medicine|February 5, 2013
Transcriptional regulation of macrophage arginase 1 expression and its role in atherosclerosisBenoit Pourcet, Inés Pineda-Torra
Methods in Molecular Biology (Clifton, N.J.)|October 27, 2012
PPAR SUMOylation: some useful experimental tipsBenoit Pourcet, Bart Staels, Corine Glineur
Methods in Molecular Biology (Clifton, N.J.)|November 11, 2015
Luciferase Reporter Assays to Assess Liver X Receptor Transcriptional ActivityMatthew C Gage, Benoit Pourcet, Inés Pineda-Torra
Expert Opinion on Emerging Drugs|August 31, 2006
Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosisBenoit Pourcet, Jean-Charles Fruchart, Bart Staels, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
The Journal of Clinical Investigation|February 20, 2018
Alternative macrophages in atherosclerosis: not always protective!Benoit Pourcet, Bart Staels
Frontiers in Immunology|August 28, 2020
Circadian Control of Inflammasome Pathways: Implications for Circadian MedicineBenoit Pourcet, Hélène Duez
Frontiers in Endocrinology|March 15, 2021
Nuclear Receptors in the Control of the NLRP3 Inflammasome PathwayHélène Duez, Benoit Pourcet
International Journal of Molecular Sciences|September 28, 2021
Nuclear Receptors and Clock Components in Cardiovascular DiseasesBenoit Pourcet, Hélène Duez
Medecine Sciences : M/S|September 12, 2022
[Nuclear receptors and circadian clock: Implications for inflammatory diseases]Hélène Duez, Benoit Pourcet
Cardiovascular Research|December 26, 2015
Perilipin2/adipophilin and ApoA-1 team up to combat atherosclerosisBenoit Pourcet, Bart Staels
Trends in Cardiovascular Medicine|February 5, 2013
Transcriptional regulation of macrophage arginase 1 expression and its role in atherosclerosisBenoit Pourcet, Inés Pineda-Torra
Methods in Molecular Biology (Clifton, N.J.)|October 27, 2012
PPAR SUMOylation: some useful experimental tipsBenoit Pourcet, Bart Staels, Corine Glineur
Methods in Molecular Biology (Clifton, N.J.)|November 11, 2015
Luciferase Reporter Assays to Assess Liver X Receptor Transcriptional ActivityMatthew C Gage, Benoit Pourcet, Inés Pineda-Torra
Expert Opinion on Emerging Drugs|August 31, 2006
Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosisBenoit Pourcet, Jean-Charles Fruchart, Bart Staels, et al.
Pageof 3